Clinical trials: Recurrent Primary Peritoneal Cancer
- Condition Recurrent Primary Peritoneal Cancer
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Ovarian Cancer, Peritoneal Cancer
A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer
The primary purpose of this trial is to estimate the drug effect on tumors in patients with ovarian or primary peritoneal cancers. Patients will receive Pemetrexed every 21 days until disease progression or unacceptable toxicity.
- Trial name
- NCT00461786
- Testing
- pemetrexed
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Eli Lilly and Company